The Lovesac Company Announces Participation in Upcoming Investor Conference STAMFORD, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, announced today that the Company is scheduled to participate in the 2025 Global Consumer & Retail Conference hosted by Telsey Advisory Group in collaboration with Santander Corporate & Investment Banking on Wednesday, October 8, 2025, at 3:30 p.m. Eastern Time. The fireside chat will be w...
The Lovesac Company Reports Second Quarter Fiscal 2026 Financial Results Q2 FY26 Net Sales Increased 2.5% to $160.5 Million vs. Q2 FY25 STAMFORD, Conn., Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the second quarter of fiscal 2026, which ended August 3, 2025. Shawn Nelson, Chief Executive Officer, stated, “We're pleased to have delivered another quarter of market share gains under...
Korro to Participate in Upcoming Investor and Scientific Conferences CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: Citi's 2025 Biopharma Back to School ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025. Cantor Global Healthcare ConferenceDr. Aiyar will pa...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
The Lovesac Company Announces Second Quarter Conference Call Date STAMFORD, Conn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its second quarter financial results will be released before market open on Thursday, September 11, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-4...
The Lovesac Company Appoints Alan Boehme to Its Board of Directors STAMFORD, Conn., Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced that Alan Boehme has been appointed to the Board of Directors, effective August 27, 2025. Andrew Heyer, Chairman of the Board of Directors, stated, "We are thrilled to welcome Alan to our Board. His exceptional track record of driving digital transformation, operational excellence,...
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates — Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro’s rare metabolic di...
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro’s investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). “The EMA...
The Lovesac Company issues Notice of Settlement of Shareholder Derivative Actions STAMFORD, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today released the following notice: A Federal Court authorized this Notice. This is not a solicitation from a lawyer. TO:ALL PERSONS OR ENTITIES WHO HOLD OR BENEFICIALLY OWN COMMON STOCK OF THE LOVESAC COMPANY AS OF MAY 19, 2025 (“SECURITIES HOLDERS”). PLEASE READ THIS NOTICE CAREFULLY AND COMPLETELY BECAUSE YOUR RIGHTS MIGHT BE AFFECTED BY T...
The Lovesac Company Reports First Quarter Fiscal 2026 Financial Results Q1 FY26 Net Sales Increased 4.3% to $138.4 Million vs. Q1 FY25 STAMFORD, Conn., June 12, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the first quarter of fiscal 2026, which ended May 4, 2025. Shawn Nelson, Chief Executive Officer, stated, “Our first quarter performance was inline with our expectations to capitalize on sec...
The Lovesac Company Announces First Quarter Conference Call Date STAMFORD, Conn., May 29, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its first quarter financial results will be released before market open on Thursday, June 12, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-493-678...
Korro to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 ...
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates —Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027 —Second development candidate expected to be announced in 2025 —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securitie...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.